B-cell activation, differentiation, and contraction

49,063views

B-cell activation, differentiation, and contraction

Joana

Joana

Mycobacterium tuberculosis (Tuberculosis)
Tuberculosis: Pathology review
Diabetes insipidus
Diabetes mellitus
Hypoglycemics: Insulin secretagogues
Thyroid cancer
Thyroid nodules and thyroid cancer: Clinical
Diabetes mellitus: Clinical
Hypertriglyceridemia
Anatomy of the thyroid and parathyroid glands
Insulins
Diabetes mellitus
Adrenal masses: Pathology review
Adrenal masses and tumors: Clinical
Adrenal insufficiency: Pathology review
Primary adrenal insufficiency
Congenital adrenal hyperplasia
Adrenal gland histology
Adrenal masses: Pathology review
Adrenal masses and tumors: Clinical
Esophageal cancer
Gastric cancer
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Peptic ulcers and stomach cancer: Clinical
Colorectal cancer
Colorectal cancer: Clinical
Metaplasia and dysplasia
Diabetic nephropathy
Benign liver tumors
Hepatocellular carcinoma
Peptic ulcer
Peptic ulcer
Helicobacter pylori
Cirrhosis
Inflammatory bowel disease: Pathology review
Inflammatory bowel disease: Clinical
Gallbladder carcinoma
Wilson disease
Pancreatic cancer
Carcinoid syndrome
Acromegaly
Viral hepatitis
Hyperthyroidism: Clinical
Alcohol-associated liver disease
Non-alcoholic fatty liver disease
Pituitary adenoma
Non-steroidal anti-inflammatory drugs
Diarrhea: Clinical
Metabolic acidosis
Metabolic alkalosis
Ulcerative colitis
Crohn disease
Respiratory acidosis
Nephrotic syndromes: Pathology review
Goodpasture syndrome
Nephritic syndromes: Pathology review
Respiratory alkalosis
Cholestatic liver disease
Laxatives and cathartics
Polycystic ovary syndrome
MEN syndromes: Clinical
Autoimmune polyglandular syndrome type 1 (NORD)
Type I and type II errors
Gastroesophageal reflux disease (GERD)
Celiac disease
Polycystic kidney disease
Chronic kidney disease
Acute kidney injury: Clinical
IgA nephropathy (NORD)
Focal segmental glomerulosclerosis (NORD)
Minimal change disease
Chronic kidney disease: Clinical
Cytomegalovirus infection after transplant (NORD)
Hyperkalemia: Clinical
Atherosclerosis and arteriosclerosis: Pathology review
Portal hypertension
Cirrhosis: Clinical
Hypercholesterolemia: Clinical
Gallbladder histology
Chronic cholecystitis
Gout
Gout and pseudogout: Pathology review
Lesch-Nyhan syndrome
Macrocytic anemia: Pathology review
Alpha-thalassemia
Beta-thalassemia
Anemia: Clinical
Sickle cell disease (NORD)
Sickle cell disease: Clinical
Aplastic anemia
Von Willebrand disease
Acute leukemia
Lung cancer: Clinical
Lung cancer
Breast cancer: Clinical
Breast cancer
Monoclonal antibodies
Atrioventricular block
Heart blocks: Pathology review
Abnormal heart sounds
Heart failure
Pulmonary embolism
Pulmonary edema
Pulmonary valve disease
Cell-mediated immunity of CD4 cells
Cell-mediated immunity of natural killer and CD8 cells
Innate immune system
Introduction to the immune system
Complement system
T-cell development
B-cell development
MHC class I and MHC class II molecules
T-cell activation
B-cell activation, differentiation, and contraction
Antibody classes
Somatic hypermutation and affinity maturation
VDJ rearrangement
Contracting the immune response and peripheral tolerance
B- and T-cell memory
Vaccinations
Type I hypersensitivity
Food allergy
Anaphylaxis
Asthma
Type II hypersensitivity
Type III hypersensitivity
Type IV hypersensitivity
Graft-versus-host disease
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
ELISA (Enzyme-linked immunosorbent assay)
Gel electrophoresis and genetic testing
Fluorescence in situ hybridization
Precipitation reactions
Isolated primary immunoglobulin M deficiency
Selective immunoglobulin A deficiency
Blood groups and transfusions
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE): Pathology review
Systemic lupus erythematosus (SLE): Clinical
Chronic granulomatous disease
Complement deficiency
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
DiGeorge syndrome
X-linked agammaglobulinemia
Hyper IgM syndrome
Leukocyte adhesion deficiency
Immunodeficiencies: Clinical
HIV (AIDS)
Cell-cell junctions
Hashimoto thyroiditis
Wiskott-Aldrich syndrome
Food allergies and EpiPens: Information for patients and families (The Primary School)
Vaccinations: Clinical
Blood products and transfusion: Clinical
Hypersensitivity skin reactions: Clinical
Shock: Clinical
Rheumatic heart disease
Immune thrombocytopenia
Rheumatoid arthritis
Rheumatoid arthritis: Clinical
Multiple sclerosis

Transcript

Watch video only

The adaptive immune response is highly specific for each invader. The cells of the adaptive immune response have receptors that differentiate one pathogen from another by their unique parts - called antigens. The key cells of the adaptive immune response are the lymphocytes - the B and T cells. B cells develop in the bone marrow where they undergo a process called VDJ rearrangement to generate a massively diverse set of B cell receptors.

The B cell receptor is essentially an antibody except that it has a transmembrane part that goes through the membrane attaching the receptor to the surface of the B cell. The B cell receptor has two heavy chains and two light chains, and the region or fragment of the B cell receptor that binds the antigen is called the fragment-antigen binding or Fab region.

The Fab region is where the ends of the heavy and light chains meet, and there are two Fab fragments on each B cell receptor. The remainder of the heavy chain makes up the fragment-crystalline region, also called Fc, which crystallizes in solution and is also constant or identical in every antibody of a particular type.

The two heavy chains are linked to one another by disulfide bonds, and each heavy chain is also linked to a light chain by a disulfide bond. Each B cell receptor has two identical heavy and light chains, resulting in two identical antigen binding sites. As the B cell develops into a plasma cell, the B cell receptor gets secreted as an antibody with the exact same antigen specificity. However, the heavy chain actually changes as the B cell develops.

There are 5 major types of heavy chains which encode the isotypes or classes of immunoglobulins: IgM, IgD, IgG, IgA, and IgE. These five are encoded by heavy chain genes which are referred to by the Greek letters mu, delta, gamma, alpha, and epsilon.

When a B cell is first developing it initially expresses the mu heavy chain, and as a result all of the B cell receptors are IgMs that are on the cell surface.

When the B cell finishes developing, it undergoes a process called alternative splicing. Alternative splicing is a process by which the cell expresses the heavy chain exons for both mu and delta allowing for both IgM and IgD to be simultaneously expressed on the surface.

At this point the B cell is mature but still naive. Having IgD on the B cell surface is a like a young adult with a driver’s license; they’re able to go out and explore the world – in the B cell’s case, that means all of the body’s lymphatic system - but the cells haven’t been exposed to much and don’t know how they’ll react to foreign antigens.

Once the B cells start to explore the body’s lymphatic system they travel from lymph node to lymph node in search of antigens.

Lymph nodes are scattered throughout your body, and each one is a highly organized structure where millions of B cells, T cells, antigens, and antigen presenting cells pass through every day - like a busy airport.

When B cells and T cells get into the lymph nodes, they first enter the paracortical region. The T cells remain there, while the B cells migrate to the neighboring cortical region of the lymph node, where they form the primary lymphoid follicles. If a B cell gets activated, it starts replicating within a follicle, and it forms a germinal center. And a follicle with a germinal center is called a secondary lymphoid follicle. Various antigens enter the lymph node through the afferent lymphatic vessel, and they percolate through the paracortex and through to the follicle. It looks a bit like a game of plinko where the antigens get to interact with lots of B cells in the follicle. B cells, unlike T cells, can recognize a wide variety of antigens including peptides, carbohydrates, and lipids in their native form, meaning that they don’t require antigen presenting cells to process or present the antigen.

In order for the B cell to be activated, the antigen first needs to bind to and induce the crosslinking of the B cell receptors. When two B cell receptors get crosslinked, their intracellular chains, the side chains - Ig alpha and Ig beta, and CD19 all cluster together. Each of these side chains have something called an immune receptor tyrosine-based activation motif, or ITAM for short. The ITAM is a conserved sequence of amino acids that includes two tyrosine amino acids. Binding of the antigen to the B-cell receptor signals the phosphorylation of these tyrosine molecules, which then triggers a chain of events within the cell that ends with the activation of the major transcription factors - NFkappaB and NFAT. These transcription factors increase the expression of certain cytokines and anti-apoptotic cell surface markers like Bcl-2, which are required for the proliferation and differentiation of B cells.

Key Takeaways

B cells are activated when they encounter an antigen that they recognize. The antigen binds to the B cell's surface receptors, which activates and triggers it to divide and differentiate into an antibody-secreting plasma cell. Plasma cells produce antibodies that bind to the antigen and neutralize it.

The differentiation process is controlled by various factors, including cytokines, lymphokines, and chemokines. Each of these molecules signals the B cells to differentiate into a certain type of plasma cell.